Blog

  • The Verification Race Every Trading Hub Must Now Enter; SMX is the Starter

    The Verification Race Every Trading Hub Must Now Enter; SMX is the Starter

    NEW YORK, NY / ACCESS Newswire / December 2, 2025 / Dubai didn’t just strengthen its gold market. It changed the competitive landscape for every major trading hub on the planet. Once the DMCC demonstrated that material-level verification could be embedded into precious metals and validated at global scale, the entire structure of international trade shifted. Traders now see what it looks like when a commodity carries its own identity. They see faster clearances, cleaner pricing, tighter compliance, and fewer disputes. And they see something else. They see that every other hub now has to play catch-up.

    SMX (NASDAQ:SMX) helped catalyze that shift by delivering molecular identity that stays with gold across its entire lifecycle. When one region adopts technology that eliminates uncertainty, every other region has to respond or accept a weakened position.

    For decades, London, Zurich, Hong Kong, Singapore, and New York competed for influence based on liquidity, heritage, and regulatory frameworks. Those advantages still matter, but they’re no longer enough. Verification has become the differentiator. Traders want to move assets with truth embedded, not truth assumed. Governments want imports and exports backed by evidence, not paperwork. Vaults want bars with scientifically validated lineage rather than variable documentation. The DMCC capitalized on this shift early and made verification part of its infrastructure. Other hubs now face a choice. Modernize or fall behind.

    What Dubai showed at the DMCC Precious Metals Conference was simple and impossible to ignore. Markets move toward certainty. They migrate toward systems where authentication is built into the material and validated by technology rather than by reputation. Dubai didn’t wait for global consensus. It built the model first. That’s why the verification race has begun.

    The Pressure on Global Hubs

    Once Dubai positioned itself as the gold market’s verification authority, the implications became global. You can’t maintain leadership in precious metals if your verification model is weaker than your competitor’s. Traders are practical. They go where the risk profile is lowest, where compliance moves smoothly, and where they can confirm the truth faster than anyone else. Dubai gives them all three. That puts pressure on every other hub in the network.

    London’s LBMA framework is world-renowned, but it wasn’t designed for a world where materials can carry forensic identity. Singapore’s bullion market is fast-growing, but it doesn’t yet offer molecular-level proof. Zurich brings stability, but its verification structure still relies on paperwork as the anchor. The moment Dubai showed that materials could carry their own identity, the benchmark shifted. Everything else now looks outdated, and that perception matters in a market where confidence and liquidity depend on certainty.

    SMX’s involvement with Goldstrom and its trueGold suite compounds that pressure. When gold bars arrive authenticated at the molecular level and connected to their full lifecycle history, the bar itself becomes a verified digital-physical asset. There’s no interpretation. No debate. No missing information. That clarity creates higher-value metals because they enter the market with less risk attached. And it forces other hubs to acknowledge that their legacy systems don’t offer the same advantage.

    The global market has seen what’s possible. Now it expects it.

    The Beginning of a Global Verification Standard

    What happens next is predictable because markets tend to reward systems that reduce friction. Verification will spread to every major hub, either because they implement it voluntarily or because participants demand it. Gold isn’t the only sector feeling the shift. The validation technology that lifted Dubai’s metals platform is the same technology SMX deployed across plastics with A*STAR in Singapore, textiles with CETI in France, and complex materials with CARTIF in Spain. Once the market sees that verification works in multiple industries, it stops being an experiment and becomes a standard.

    Trading hubs won’t adopt molecular identity because Dubai did. They’ll adopt it because their traders, regulators, and institutional partners will refuse to operate without it. Imagine submitting a shipment to London that isn’t verifiable at the material level when Dubai accepts nothing less. Imagine competing for liquidity when one market offers proof, and another offers promises. Imagine global insurers lowering risk assessments for verified hubs while penalizing those that rely on legacy documentation. That’s how competitive gaps widen. Technology moves first. Markets follow. Institutions enforce it.

    The verification race isn’t symbolic. It’s structural. It determines who leads the next era of global commodities trade. Hubs that embrace verification will attract liquidity, strengthen compliance frameworks, and build reputational advantage. Hubs that don’t will watch traders migrate toward markets that eliminate uncertainty instead of managing it.

    Dubai set the pace. SMX delivered the technology. Verification will be the new standard, and the race to meet it has already begun.

    About SMX

    As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

    Forward-Looking Statements

    The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

    Contact: info@securitymattersltd.com

    SOURCE: SMX (Security Matters) Public Limited

    View the original press release on ACCESS Newswire

  • Victory+ and MASL Team Up to Broadcast Entire 2025-26 Indoor Soccer Season

    Victory+ and MASL Team Up to Broadcast Entire 2025-26 Indoor Soccer Season

    Expanded partnership brings every MASL matchup to fans nationwide as U.S. interest in the sport reaches new heights.

    DALLAS, TX / ACCESS Newswire / December 2, 2025 / Victory+™, the premium sports streaming platform from A Parent Media Co. Inc. (APMC), today announced a significant expansion of its partnership with the Major Arena Soccer League (MASL). Effective immediately, Victory+ will serve as the comprehensive streaming home for the MASL, broadcasting every match of the 2025-2026 season. Of these broadcasts, over 75 will be streamed live, with the remaining 18 available on demand within 24 hours of the game. 

    The MASL regular season, which kicked off November 28 and runs through March, represents the highest level of professional indoor soccer in the world. Its eight U.S.-based teams feature elite players representing more than 50 countries, bringing a global flavor and fast-paced energy to every match.

    “We’re seeing explosive momentum behind soccer fandom globally and especially here at home,” said Jason Walsh, COO of Victory+. “With the 2026 World Cup set to unfold in our own backyard, interest in the sport is only intensifying. Expanding our partnership with the MASL allows us to meet that surge head-on, offering fans the premium, high-adrenaline indoor soccer experience they’re looking for.”

    This partnership extension comes at a time when the sport is skyrocketing in cultural relevance. According to a recent Harris Poll, 72% of Americans now express an interest in soccer, up 17% since 2020, with one in five describing themselves as “obsessed.” To serve this rapidly growing fanbase, Victory+ is building a robust soccer portfolio anchored by a milestone NWSL deal,  securing the largest share of games in 2026, and bolstered by coverage from the MASL.

    “Victory+ meets fans where they are with the access they crave,” said JP Dellacamera, President of Communications/Media, MASL. “Partnering with this game-changing, free-to-consumer platform allows us to extend our reach and introduce the intensity of the MASL to the next generation of fans.”

    Built for the future of fandom, Victory+ is on a mission to break down barriers for sports fans. With a rapidly expanding content lineup, the platform is becoming the go-to destination for fans nationwide. Beyond live access, Victory+ levels up the fan experience with exclusive in-game perks, next-level prizes, and behind-the-scenes content, making it the place where fans come to win.

    For more information on Victory+ including schedules, exclusive content, and more visit www.victoryplus.com.

    ABOUT APMC

    A Parent Media Co. Inc (APMC) is a global technology company building audience-first products that connect millions of people across the world with the brands they love. With a diverse portfolio of free, ad-supported products that include platforms Kidoodle.TV®, Dude Perfect Streaming Service, Glitch+™, Victory+™, and groundbreaking ad technology Safe Exchange™ APMC delivers brand-safe media that builds meaningful connections.

    Powered by advanced streaming infrastructure, APMC platforms engage audiences across thousands of devices in more than 160 countries-redefining global reach. By combining flexible monetization models, real-time audience insights, and customizable brand integrations, the APMC network empowers partners to accelerate growth and unlock new revenue at scale.

    APMC is challenging outdated models and breaking down barriers, ensuring that everyone, everywhere can access the content they love.

    ABOUT Victory+

    Victory+ is a free, sports streaming platform that puts fans first, giving them direct access to the teams and leagues they love. It features regional broadcasts of teams including the Dallas Stars, Anaheim Ducks, and Texas Rangers, along with national coverage of highly popular leagues such as the WHL and NWSL. Victory+ is also the home to a library of on-demand, premium sports-based, outdoors, and extreme sports content.

    Learn more at www.victoryplus.com and www.aparentmedia.com

    Media Contact: media@aparentmedia.com

    ABOUT MASL

    The Major Arena Soccer League represents the highest level of professional indoor soccer in the world. The MASL features teams across the U.S. with players from over 50 countries. The MASL is currently incorporated as a 501(c)6 not for profit corporation formed to promote the business and sport of indoor soccer.

    Contact Information

    Madeleine Moench
    madeleine@newswire.com

    Jeremy Mason
    Chief Brand Officer
    media@aparentmedia.com

    .

    SOURCE: A Parent Media Co. Inc.

    Related Images

    View the original press release on ACCESS Newswire

  • Finexio and RipplePoint Forge Strategic Partnership to Revolutionize Hospitality Financial Operations

    Finexio and RipplePoint Forge Strategic Partnership to Revolutionize Hospitality Financial Operations

    Industry-Leading B2B Payments Platform partners with Premier Expense Analytics Solution to Drive Unprecedented Value for Hotels, Resorts, and Restaurant Groups

    ORLANDO, FL / ACCESS Newswire / December 2, 2025 / Finexio, the pioneering Accounts Payable Payments-as-a-Service platform, today announced a transformative strategic partnership with RipplePoint, the hospitality industry’s premier SaaS expense analytics platform trusted by hundreds of properties for over 20 years. This landmark collaboration delivers an end-to-end financial transformation solution that empowers hospitality operators to achieve 30-60% cost reductions while converting accounts payable from a cost center into a profit generator.

    The $570 billion hospitality industry faces unprecedented operational complexity, managing thousands of supplier relationships across multiple locations while navigating diverse ownership structures and brand requirements. With labor costs at historic highs and operational efficiency paramount, forward-thinking hospitality groups are seeking integrated technology solutions that deliver both immediate cost relief and sustainable competitive advantages.

    Transformative Solution for a Critical Industry Need

    RipplePoint’s comprehensive evaluation of the payments landscape identified Finexio as the only partner capable of delivering the sophisticated, embedded infrastructure required for true financial transformation. The partnership addresses a critical industry pain point: hotels and restaurants currently spend 10-15 hours weekly on manual AP tasks while leaving millions in potential revenue on the table through inefficient payment methods.

    Through this collaboration, hospitality operators gain access to institutional-grade payment capabilities previously available only to Fortune 500 companies. The integrated solution delivers:

    • Revenue Generation: Transform AP spend into cash back earnings through optimized virtual card programs, directly improving bottom-line profitability

    • Operational Excellence: Reduce AP processing time by 70% through intelligent automation and seamless supplier onboarding

    • Enterprise Security: Bank-grade fraud protection powered by JPMorgan’s infrastructure shields operations from payment fraud and cyber threats

    • Actionable Intelligence: Combined analytics and payment data provide unprecedented visibility into spend patterns and optimization opportunities

    “In today’s hospitality landscape, operational excellence and financial optimization are not just competitive advantages, they are survival imperatives,” said Ernest Rolfson, CEO and Founder of Finexio. “By partnering with RipplePoint, we’re delivering a solution that fundamentally transforms how hospitality businesses manage their financial operations. Our combined platform doesn’t just reduce costs; it creates new revenue streams, enhances security, and provides the financial intelligence needed to thrive in an increasingly complex industry. This partnership represents a paradigm shift in hospitality financial management.”

    “Our partnership with Finexio represents a watershed moment for the hospitality industry,” said Dustin Reineke, President and CEO of RipplePoint. “For over 20 years, we’ve helped hospitality operators achieve dramatic cost reductions through our analytics platform. By providing Finexio’s best-in-class payment capabilities to our customer base, we’re now able to deliver a complete financial transformation solution that addresses every aspect of expense management and payment processing. This is a revolution in how hospitality businesses approach financial operations.”

    Measurable Impact and Proven Results

    Adopter of the Finexio-RipplePoint solution will experience transformative results. Properties using the solution have reported recovering 10-15 hours of staff time weekly, achieving at least 1% cash back on eligible AP spend, and realizing immediate cost savings through RipplePoint’s proven optimization strategies. The solution’s sophisticated approach respects the unique operational rhythms of hospitality while delivering enterprise-grade capabilities that scale from independent hotels to major chains.

    The Finexio payment automation solution is immediately available to all RipplePoint customers. New customers interested in transforming their financial operations can visit www.finexio.com or contact Bobby Schmidt, Head of Sales & Marketing, at bobby@finexio.com.

    About Finexio

    Finexio is transforming B2B payments through its revolutionary Accounts Payable Payments-as-a-Service platform. Processing billions annually across thousands of businesses, Finexio’s AI-powered solution seamlessly embeds within leading Procure-to-Pay and ERP systems to optimize, monetize, and secure the entire payment lifecycle. With a proven track record of delivering exceptional value to hospitality operators and strategic partnerships with industry leaders, Finexio enables businesses to eliminate paper checks, reduce processing costs by up to 80%, and transform AP departments into profit centers. The company’s innovative approach has earned recognition as a leader in embedded B2B payments, trusted by companies ranging from emerging brands to public institutions. Learn more at www.finexio.com.

    About RipplePoint

    RipplePoint is the hospitality industry’s leading SaaS expense analytics and technology optimization platform, delivering measurable cost savings and operational efficiencies for over 20 years. Trusted by hundreds of hotels, resorts, and restaurant groups, RipplePoint’s proprietary business intelligence platform provides comprehensive visibility into technology spending while identifying and implementing cost reduction opportunities that typically achieve 30-60% savings. Beyond software analytics, RipplePoint offers expert project management services for technology implementations, from new hotel builds to major renovations, ensuring successful outcomes for business-critical initiatives. The company’s unique combination of deep hospitality expertise, powerful analytics capabilities, and hands-on implementation support has generated millions in documented savings for clients while establishing RipplePoint as an essential partner for hospitality operators seeking to maximize profitability through intelligent expense management. Learn more at www.ripplepoint.com.

    Contact Information

    Bobby Schmidt
    Head of Sales & Marketing
    bobby@finexio.com
    (678)334-1292

    .

    SOURCE: Finexio

    View the original press release on ACCESS Newswire

  • SMX Has Filled the Plastics Profit Gap that Cost Companies Billions

    SMX Has Filled the Plastics Profit Gap that Cost Companies Billions

    NEW YORK, NY / ACCESS Newswire / December 2, 2025 / Recycled plastics should be one of the most profitable materials in the global supply chain. Every major brand wants more of it, governments are pushing mandates, and consumers expect companies to cut reliance on virgin polymers. Yet recycled plastics still sell at a discount. Markets don’t fully trust the labels, suppliers can’t prove what they’re shipping, and buyers assume they’re paying for content that might not be real. The spread between what recycled plastics should be worth and what companies actually earn has turned into a persistent profit gap. SMX (NASDAQ:SMX) is closing that gap by giving plastics something they’ve never had. They get a verifiable identity that survives every transformation.

    The recycled plastics market is full of claims without certainty. Suppliers insist their pellets contain 30%-50% recycled content, but they lack molecular evidence to support that claim. Brands reveal sustainability commitments, but they rely on third-party forms that don’t reflect what happens across international recycling streams. Governments demand accuracy, but they’re stuck reviewing documentation that’s often outdated or fragmented. Companies lose money because they can’t prove value. Buyers discount prices because they can’t trust inputs. That cycle has held the entire sector back for years.

    SMX changes that by embedding a molecular-level identifier into plastics that stays intact through every process. The identity doesn’t wash out during shredding. It doesn’t disappear during melting. It survives extrusion, molding, and reprocessing. When a batch of recycled pellets arrives at a manufacturer, identity confirmation verifies exactly what the plastic contains and where it originated. Suddenly, recycled content is no longer a claim. It’s proof. And proof commands a premium.

    Why Trust Drives Value in Plastics Markets

    The plastics sector, more than almost any other, depends on trust because recycled feedstocks are inconsistent across regions, processors, and collection systems. Two suppliers may list the same grade on a sheet, but the actual material can behave differently in production. That uncertainty costs brands time, money, and credibility. When buyers can’t verify recycled content, they reduce their bids. When manufacturers can’t guarantee consistency, they overengineer products to compensate. When regulators can’t validate reports, they add layers of reporting that slow down the entire system.

    This is where strategic partnerships show the practical impact of material identity. SMX’s collaboration with Tradepro in the United States proves how authentication changes market behavior. Manufacturers that used to hedge against uncertainty can, if all goes as planned, choose verified recycled plastics that carry embedded truth. The material isn’t anonymous anymore. It arrives with evidence. That shift alone lifts margins for suppliers who previously watched their prices suppressed by doubt.

    The REDWAVE collaboration in Austria shows another side of the advantage. High-speed optical sorting gains precision when the material entering the system carries its own identification. Instead of relying on shape or color, the line reads molecular identity. That allows more accurate separation, more consistent output, and higher-grade recycled plastics that fetch stronger pricing. Markets begin rewarding quality because quality becomes measurable.

    When plastics tell the truth about themselves, the value follows the evidence. Buyers start paying more for verified content. Brands start meeting sustainability goals without fear of greenwashing allegations. Recyclers start commanding higher margins for authenticated outputs. Trust isn’t a belief anymore. It’s a property.

    How Proof Rewrites Sustainability and Profitability

    The plastics industry has spent a decade trying to balance sustainability with economic reality. Companies want to increase recycled content, but they can’t expose themselves to risk. Regulators want accuracy, but they can’t rely on reporting alone. Investors want transparency, but they need real data, not estimates. Every stakeholder wants the same thing. They want evidence without friction.

    That’s why the A*STAR program in Singapore became a breakthrough moment. When SMX’s identity technology was deployed within national-scale circularity pilots, recycled plastics gained trackable lineage across collection, recovery, reuse, and manufacturing. The system didn’t assume accuracy. It verified it. A plastic bottle didn’t disappear into the system. It traveled through it with identity intact.

    That level of truth gives governments a way to enforce recycling goals without slowing down industry. It gives brands a way to meet their commitments with confidence. It gives recyclers a way to get paid what their material is truly worth. The result is a plastics market that finally behaves like a real commodity market. Verified content sells at a premium because the risk disappears. Supply chains run cleaner because fraud becomes pointless. Regulators gain visibility without adding complexity. Investors see rising margins instead of structural discounts. Verification becomes the economic engine that the plastics market has been missing.

    That closes the gap between what recycled plastics should be worth and what companies actually earn. SMX built the technology that transforms recycled plastics from a discounted material into a premium one. When the market knows the truth, the market pays for the truth. The companies able to prove it will redefine the economics of sustainability. And, more importantly, make money at the same time.

    About SMX

    As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

    Forward-Looking Statements

    The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

    Contact: info@securitymattersltd.com

    SOURCE: SMX (Security Matters) Public Limited

    View the original press release on ACCESS Newswire

  • Trial Library Raises $10 Million Series A to Expand Access to Clinical Trials as a Care Option

    Trial Library Raises $10 Million Series A to Expand Access to Clinical Trials as a Care Option

    Co-led by SemperVirens Venture Capital and Next Ventures, with participation by Sanofi Ventures, Lux Capital, Civilization Ventures, How Women Invest and other notable investors

    SAN FRANCISCO, CA / ACCESS Newswire / December 2, 2025 / Trial Library, an AI-enabled platform expanding access to clinical trials as a care option, announced a $10 million Series A funding round co-led by SemperVirens Venture Capital and Next Ventures, with participation from Sanofi Ventures, Lux Capital, Civilization Ventures, How Women Invest, Overwater Ventures and others. This investment, which brings total funding to date of $15 million, accelerates Trial Library’s mission to make clinical research a core part of standard of care – bridging access gaps for patients, empowering healthcare providers and aligning payers and biopharmaceutical sponsors around a more efficient and equitable research ecosystem.

    “As a physician-scientist, I witnessed, first-hand, the significant impact clinical trials have on improved healthcare outcomes. At Trial Library, we’re building the connective tissue that links care delivery and clinical research,” said Dr. Hala Borno, CEO and founder of Trial Library. “This latest funding will enable us to advance our model where access to innovation is the standard, not the exception.”

    Trial Library’s platform unlocks access to clinical trials in community-based clinical settings through AI-enabled provider activation, compliant eligible patient identification and longitudinal navigation throughout the trial lifecycle.Trial Library currently operates across 320+ clinics and 1,500+ providers nationwide and is rapidly expanding its network alongside growing partnerships with payers such as self-insured plans and health plans.

    “Trial Library is the first technology company to unlock the payer market to effectively broaden the pool of patients who are considered for clinical trials,” said Allison Baum Gates, general partner of SemperVirens Venture Capital. “We’re excited to back a platform that aligns incentives and unites patients, providers, payers, and life-science partners around shared cost-savings and patient outcomes.”

    Trial Library has partnered with leading global biopharmaceutical companies to accelerate R&D and enrollment. “Trial Library is a uniquely end-to-end platform, building the AI infrastructure that is accelerating access to the next generation of precision medicine,” said Cris De Luca, partner at Sanofi Ventures.

    Since launching in 2022, Trial Library has demonstrated significant impact through strategic partnerships with leading healthcare organizations. The company’s work with The Oncology Institute generated 642 patient referrals in one year, while partnerships with American Oncology Network have identified tens of eligible patients for solid tumor trials in just the first quarter of implementation. Trial Library’s platform has also expanded its collaboration with Johnson & Johnson Innovative Medicine to support oncology clinical development and medical affairs programs, and in 2025 the company announced a collaboration with Texas Oncology to streamline clinical trial access through personalized patient navigation

    “Trial Library’s approach aligns with the growing shift toward decentralized, community-based research,” said Lance Armstrong, managing partner at Next Ventures. They’re proving that AI and human navigation together can bring precision medicine to every corner of healthcare.”

    Trial Library is committed to diversity and equity among patient populations, including a focus on underserved populations. This includes 69% of patient referrals being non-white, 29% on Medicaid and 44% requiring transportation support. This effort addresses critical gaps in clinical trial participation while reducing administrative burden on providers and transforming how community oncology practices engage with clinical research.

    About Trial Library

    Trial Library is an AI-platform that accelerates access to precision medicine. In collaboration with biopharmaceutical manufacturers, payers and health systems, Trial Library enables the delivery of clinical trials as a care option, advancing access to precision medicine, improving oncology outcomes and reducing the total cost of care. Backed by some of the leading venture capital firms in healthcare, Trial Library currently operates across 320+ clinics and 1,500+ providers nationwide. Learn more at www.triallibrary.com.

    Media Contact

    Lizi Sprague, Songue PR
    lizi@songuepr.com

    SOURCE: Trial Library

    View the original press release on ACCESS Newswire

  • Barron Designs Launches Acoustic Panels Collection for Stylish Sound Control

    Barron Designs Launches Acoustic Panels Collection for Stylish Sound Control

    New Slat Wood Panels Combine High-Performance Acoustics With Modern, Design-Driven Appeal

    ALBEMARLE, NC / ACCESS Newswire / December 2, 2025 / Barron Designs, a trusted leader in architectural design products for over 50 years, announces the launch of its Acoustic Panels Collection – a line of slat wood wall panels that combine modern visual appeal with effective sound absorption. Designed for both residential and commercial use, these panels offer a versatile avenue for improving acoustics while enhancing interior style.

    Barron Designs' Acoustic Paneling Seen In Modern Home Living Room Accent Wall
    Barron Designs’ Acoustic Paneling Seen In Modern Home Living Room Accent Wall
    Barron Designs Launches Acoustic Panels Collection for Stylish Sound Control. See the Acoustic Paneling in a stunning modern living room design.

    Each panel features a felt acoustic backing with sleek vertical wood slats, creating a modern linear texture that adds depth and warmth to any space. Offered in five curated finishes-Teak, Walnut, Maple, Oak, and Natural-the collection complements a wide range of styles, from clean minimalism to bold contemporary. These wood tones and grain patterns transform functional acoustics into a refined architectural statement.

    “This launch reflects our commitment to design solutions that are both practical and beautiful,” said Amy Burgess, Director of Product and Channel Marketing at Barron Designs. “These acoustic panels give our customers the power to completely reimagine their space-visually and acoustically-without having to choose between style and performance.”

    The panels offer a baseline NRC rating of 0.45, which can increase to Class A sound absorption depending on installation method and backing material. They install easily using adhesive or screws, making them ideal for home offices, creative studios, restaurants, and open-plan environments.

    While Barron Designs is best known for its custom-crafted decorative beams and wall panels, the Acoustic Panels collection expands its portfolio to meet growing demand for design-forward acoustic solutions. Each panel is made from FSC® Certified wood, supporting responsible forestry and low-VOC emissions. An integrated antibacterial coating enhances cleanliness in high-traffic and hospitality settings, while a Fire Reaction rating of Class B-s1, d0 ensures dependable safety across diverse interior environments.

    About Barron Designs
    Barron Designs is a leading manufacturer and distributor of exceptionally crafted architectural décor products, including faux and real wood beams, faux wall panels, decorative columns, and exterior siding. Founded in 1972, the company serves DIYers, designers, contractors, and architects nationwide, offering visually striking, easy-to-install solutions that stand the test of time. Learn more at www.barrondesigns.com.

    Contact Information:

    Amy Burgess
    Director of Product and Channel Marketing
    aburgess@mckenziecreativebrands.com
    800-651-4223

    .

    SOURCE: Barron Designs

    View the original press release on ACCESS Newswire

  • Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

    Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

    ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, is pleased to announce that on November 3, 2025, it submitted its Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration (FDA). The submission concerns the Company’s lead product candidate, a fast-acting, high-dose sublingual aspirin formulation for the treatment of suspected acute myocardial infarction (AMI) and represents a significant milestone on the path to potential FDA approval.

    The Pre-IND meeting initiates formal dialogue with the FDA and is intended to gain agency guidance on the clinical development strategy and confirm the proposed 505(b)(2) regulatory pathway for Aspire’s sublingual aspirin. Gaining this clarity is a critical step toward the Company’s goal of submitting a New Drug Application (NDA).

    “Our clinical data is not just promising; it’s a breakthrough in MCI treatment. We demonstrated that our sublingual formulation begins to inhibit platelet aggregation in under two minutes, acting approximately four to five times as fast as chewed aspirin,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “This rapid action, confirmed with a statistical significance of p<0.02, represents a clear and potentially life-saving advantage over the current standard of care. In a heart attack, every second saved translates to preserved heart muscle. We are eager to present this compelling evidence to the FDA and define an efficient path to bring this superior treatment to patients.”

    Aspire’s confidence is rooted in the breakthrough final results of its recent clinical trial. The study showed that Aspire’s investigational product produced significantly higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA), the active form of aspirin, compared to chewed aspirin tablets (p<0.05). This was demonstrated clearly in the recent trial by the lowered levels of serum thromboxane B2 (TxB2), a key biomarker for reduced platelet accumulation, within the first two minutes after dosing (p<0.02) with Aspire’s sublingual aspirin, acting approximately four to five times faster than chewed conventional aspirin. This rapid pharmacological action demonstrates a clear and clinically meaningful superiority over the current standard of care.

    The product was also observed to be safe and well-tolerated. These results underscore the potential for Aspire’s sublingual aspirin to provide a more rapid and reliable treatment for the 800,000+ people in the U.S. who suffer a heart attack each year.

    The Company intends to pursue a 505(b)(2) regulatory pathway for its sublingual aspirin product. This streamlined pathway allows the FDA to consider data from previous studies on an already-approved drug, such as aspirin, which can potentially reduce the time and cost of development.

    This milestone for the lead aspirin program also serves as a key validation of Aspire’s versatile sublingual delivery platform, which is being applied to a pipeline of other high-value programs.

    About Aspire Biopharma Holdings, Inc.

    Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

    For more information, please visit www.aspirebiolabs.com

    Safe Harbor Statement

    This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

    Aspire Biopharma Holdings, Inc.

    Contact

    Brett Maas
    Hayden IR: (646) 536-7331
    brett@haydenir.com

    James Carbonara
    Hayden IR: (646)-755-7412
    james@haydenir.com

    SOURCE: Aspire Biopharma Holdings, Inc.

    View the original press release on ACCESS Newswire

  • Strive Pharmacy Breaks Ground on New 350,000 Sq. Ft. Arizona Headquarters and Compounding Facility, Strengthening Its National Leadership in Patient-Focused Innovation

    Strive Pharmacy Breaks Ground on New 350,000 Sq. Ft. Arizona Headquarters and Compounding Facility, Strengthening Its National Leadership in Patient-Focused Innovation

    New Mesa campus deepens Strive’s roots in Arizona, expands production capabilities, and accelerates job creation as the company surpasses 700,000 sq. ft. of national operations.

    MESA, AZ / ACCESS Newswire / December 2, 2025 / Strive Pharmacy, a national leader in patient-centered pharmaceutical compounding, officially broke ground today on its new 350,000-square-foot headquarters and advanced compounding facility in Mesa, Arizona. The milestone marks a significant step in Strive’s long-term growth plan and deepens its commitment to the state where the company was founded.

    More than just an expansion of physical space, the new Arizona headquarters represents Strive’s continued investment in innovation, workforce development, and world-class patient care. The facility will serve as the company’s operational home base, supporting national fulfillment, accelerating production capacity, and creating significant new job opportunities across the Greater Phoenix region.

    “This new headquarters is an investment in Arizona, in our team, and in the future of patient-focused medicine,” said Nate Hill, CEO and co-founder of Strive Pharmacy. “Arizona is where Strive started, and this project allows us to build the infrastructure, technology, and talent necessary to meet growing demand while staying true to our mission never to settle, especially when people’s health is at stake.”

    The building will give Strive a unique advantage-meeting the needs of existing and growing demand for personalized care, while also being built from the ground up to enable operational agility to pivot, adjust, and adapt with patient needs, industry advancements, or potential drug shortages.

    Attendees of an upcoming groundbreaking event will receive a first look at Strive’s plans for the new campus, including dedicated spaces for state-of-the-art compounding, fulfillment automation, training facilities, and expanded administrative operations. Community leaders, partners, healthcare providers, and team members will gather for a brief ceremony, a discussion on Strive’s vision for the future, and a light brunch.

    “When we invest in our facilities, we’re investing directly in patients and providers,” said Mike Walker, President and co-founder of Strive Pharmacy. “This headquarters will anchor the systems, quality controls, and service levels that define Strive. It’s a home built for the next decade of innovation.”

    The Arizona groundbreaking comes on the heels of major expansion milestones for Strive. Within the next 12 months, the company will operate more than 700,000 square feet of advanced pharmaceutical facilities nationwide, including a newly acquired 275,000-square-foot cGMP manufacturing site in Alachua, FL, and a recently expanded Tampa location designed to enhance patient experience and fulfillment speed across the Southeast.

    “Quality isn’t a step in our process, it is the process,” said Matthew Montes de Oca, Chief Compliance/Clinical Officer at Strive Pharmacy. “From rigorous weekly potency testing to independent sterility validation, every safeguard we build into this facility has one purpose: ensuring patients receive medicine that is precisely made, thoroughly verified, and genuinely personal to their needs.”

    Together, these investments position Strive as the largest and most advanced compounding pharmacy network in the United States, supporting unprecedented production scale and elevated quality standards.

    “At Strive, we’re not simply growing, we’re evolving,” added Walker. “Every square foot we build is designed to improve access, elevate quality, and deliver care with transparency and compassion.”

    About Strive Pharmacy

    Strive Pharmacy is on a mission to make personalized medicine mainstream. With a strong focus on quality, customization, and a commitment to putting people over profit, Strive Compounding Pharmacy is redefining what personalized healthcare can look like-one prescription at a time. Whether through brick-and-mortar partnerships or innovative telehealth collaborations, Strive Compounding Pharmacy continues to push the boundaries of what’s possible in modern medicine. For more information, visit Strive Compounding Pharmacy’s website at https://www.strivepharmacy.com/.

    Media Contact:
    Zach Shurtleff
    Chief Marketing Officer
    zach@strivepharmacy.com
    www.strivepharmacy.com

    SOURCE: Strive Pharmacy

    View the original press release on ACCESS Newswire

  • Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

    Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

    Jaguar’s requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia®

    A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary emergency hospitals

    SAN FRANCISCO, CA / ACCESS Newswire / December 2, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), today announced that its Italian subsidiary, Napo Therapeutics S.p.A., has submitted a request to the European Medicines Agency (EMA) to have the EMA’s Committee for Veterinary Medicinal Products (CVMP) provide scientific advice regarding the company’s plan to pursue approval of Canalevia (crofelemer delayed-release tablets) in the European Union for treatment of general diarrhea in dogs based on data from a study Jaguar completed in 200 dogs in 2017. The request asks that the CVMP review the company’s plan and related data during the CVMP’s scheduled meeting in March 2026.

    The EMA is the EU’s equivalent of the U.S. Food and Drug Administration (FDA). Canalevia, under the name Canalevia-CA1, is conditionally approved by the FDA as an oral prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

    “In the study of 200 dogs with general diarrhea, the pre-specified primary endpoint was not met. However, an updated analysis using a simplified endpoint – defining treatment success as no further episodes of diarrhea after the first treatment – showed that dogs treated with Canalevia had significantly better outcomes than those receiving placebo, including fewer watery stools and improved fecal scores,” said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar’s Vice President of Preclinical and Nonclinical Studies.

    “We provided the CVMP with a summary of the updated analysis of the data from our completed study, which we look forward to having the CVMP review,” Dr. Guy said. “Following the start of the procedure in mid-January, the EMA will have 60 days (extendable to 90) to indicate if they agree that this updated analysis would support approval of Canalevia for treatment of general diarrhea in dogs in the EU. If the EMA agrees that the updated analysis would support approval, the company will submit a Marketing Authorization Application to the EMA for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries.”

    Data from the European Pet Food Industry Federation indicates that there were 69,359,000 dogs in the EU in 2023. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the US in 2024, with nearly half (45.5%) of US households owning a dog in 2024.

    “We’ve been pleased with the marketplace reception of crofelemer for treatment of CID in dogs in the US and see a meaningful opportunity in the much larger market of general diarrhea in dogs, both in the US and the EU. We estimate that US veterinarians see approximately 6 million annual cases of acute and chronic diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “Our primary objective for Canalevia is to secure a partner to help fund and execute development and commercialization globally for treatment of general diarrhea in dogs, while we continue to support availability for CID in dogs in the US. We have made business development around general diarrhea in dogs a key focus and potential catalyst for Jaguar in 2025.”

    Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs.

    About Canalevia® and Canalevia®-CA1

    Canalevia contains crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics.

    Canalevia-CA1 (crofelemer delayed-release tablets), available from multiple leading veterinary distributors in the US, including Chewy, is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) Designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

    About Conditional Approval and Full Approval

    Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year, with up to four annual renewals, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

    About Chemotherapy-induced Diarrhea (CID) in Dogs

    According to the American Veterinary Medical Association, approximately 1 in 4 dogs will at some stage in their life develop cancer. Nearly half of dogs over 10 will develop cancer.1 According to the National Cancer Institute at the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs yearly in the US.

    Due to the increasing number of chemotherapeutic agents, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the US veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

    Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.

    Important Safety Information About Canalevia®-CA1

    For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

    Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

    About the Jaguar Health Family of Companies

    Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

    For more information about:

    Jaguar Health, visit https://jaguar.health

    Napo Pharmaceuticals, visit napopharma.com

    Napo Therapeutics, visit napotherapeutics.com

    Magdalena Biosciences, visit magdalenabiosciences.com

    Canalevia-CA1, visit canalevia.com

    Forward-Looking Statements

    Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it may identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the US and/or globally, Jaguar’s expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of the study Jaguar completed in 200 dogs with general diarrhea, Jaguar’s expectation that, if the submitted summary of the updated analysis of the data from the company’s completed study is acceptable to the EMA, the company will then submit a MAA for Canalevia for general diarrhea in dogs, and Jaguar’s expectation that, if the MAA is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    1 “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

    2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

    Contact:

    hello@jaguar.health
    Jaguar-JAGX

    SOURCE: Jaguar Health, Inc.

    View the original press release on ACCESS Newswire

  • OpenAI Joins the Global Anti-Scam Alliance as Foundation Member to Strengthen Global Response Against AI-Enabled Scams

    OpenAI Joins the Global Anti-Scam Alliance as Foundation Member to Strengthen Global Response Against AI-Enabled Scams

    New partnership marks a significant step forward in the shared mission to combat AI-enabled fraud and strengthen digital safety worldwide.

    THE HAGUE, NL / ACCESS Newswire / December 2, 2025 / As scammers adopt increasingly sophisticated methods powered by artificial intelligence, global coordination and responsible innovation have become essential to protecting consumers. Today, the Global Anti-Scam Alliance (GASA) and OpenAI announce that OpenAI has joined GASA as a Foundation Member, marking a significant step forward in the shared mission to combat AI-enabled fraud and strengthen digital safety worldwide.

    OpenAI is an AI research and deployment company whose mission is to ensure AI benefits all of humanity. The company heavily invests in safety and misuse prevention, including efforts to detect and disrupt malicious attempts to use AI systems for scams, phishing, fraud, and other harms. OpenAI also publicly shares lessons from this work to strengthen collective defenses and reinforce its commitment to transparency and responsible deployment.

    “The rise of AI enabled scams demands coordinated action across technology, policy, and law enforcement. OpenAI’s efforts to detect and disrupt malicious use of AI systems align closely with our mission. Their decision to join GASA as a Foundation Member sends a strong signal that protecting consumers in the age of AI requires shared intelligence, shared responsibility, and shared purpose,” said Jorij Abraham, Managing Director of GASA.

    “Scams are one of the fastest-growing threats people face online, and our tools are increasingly good at spotting them. That’s why OpenAI is joining the Global Anti-Scam Alliance, where we can share insights, strengthen our collective defenses, and help people stay safe. This work fits squarely within our mission to build AI tools that benefit all of humanity,” said Will McCants, Head of Intelligence and Investigations at OpenAI.

    By joining GASA as a Foundation Member, OpenAI will contribute to global research, the global advisory board, and cross-sector collaboration focused on reducing the impact of AI-enabled scams. This partnership strengthens the collective effort to build safer digital ecosystems and ensure that innovation is supported by safeguards, accountability, and shared intelligence.

    Read the full release here.

    Contact Information

    Metje van der Meer
    Marketing Director
    metje.vandermeer@gasa.org

    .

    SOURCE: Global Anti-Scam Alliance

    Related Images

    OpenAI Joins GASA
    OpenAI Joins GASA

    View the original press release on ACCESS Newswire